Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Waldenström's Macroglobulinemia (WM) Clinical Trial

Official title:
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval

Status Not yet recruiting

Clinical Trial Summary

This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian Compassionate Use Program (CUP) and receiving zanubrutinib following its commercial approval.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Waldenstrom Macroglobulinemia
Waldenström's Macroglobulinemia (WM)

Clinical Trial Details

NCT number	NCT06441214
Study type	Observational
Source	Fondazione Italiana Linfomi - ETS
Contact	Samantha Dattoli
Phone	+390599769916
Email	sdattoli@filinf.it
Status	Not yet recruiting
Phase
Start date	July 2024
Completion date	July 2026

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06043011` - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
	Completed	`NCT03332173` - Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)	Phase 2